What is it about?
Glaucoma is the second most prevalent eye condition, after cataracts, known to cause irreversible blindness in the world. Currently, the only modifiable risk factor for the progression of this disease is intraocular pressure (IOP). This article aims to evaluate the hypotensive potential of topical calcium channel blockers in glaucoma management, based on our current knowledge about this disease.
Featured Image
Why is it important?
Multiple studies have shown the relevancy and effectiveness of topical calcium channel blockers as an alternative hypotensive therapy in glaucoma management. Taken into account that not all calcium channel blockers are equally effective, the challenge for future research will be to determine the best type of calcium channel blocker.
Perspectives
It is very important to find new noninvasive treatment options for Glaucoma with non only hypotensive, but also neuroprotective, neuroresque properties.
Prof., Dr Marianne M Shahsuvaryan
Yerevan State Medical University Named after Mkhitar Heratsi
Read the Original
This page is a summary of: Cutting-edge Advancement in the Therapy of Glaucoma, Journal of Life Medicine, July 2014, American V-King Scientific Publishing,
DOI: 10.14511/jlm.2014.020301.
You can read the full text:
Contributors
The following have contributed to this page
